Volibo Tablet

Alpha-glucosidase inhibitors are saccharides that act as competitive inhibitors of enzymes needed to digest carbohydrates: specifically alpha-glucosidase enzymes in the brush border of the small intestines. The membrane-bound intestinal alpha-glucosidases hydrolyze oligosaccharides, trisaccharides, and disaccharides to glucose and other monosaccharides in the small intestine. Acarbose also blocks pancreatic alpha-amylase in addition to inhibiting membrane-bound alpha-glucosidases. Pancreatic alpha-amylase hydrolyzes complex starches to oligosaccharides in the lumen of the small intestine. Inhibition of these enzyme systems reduces the rate of digestion of complex carbohydrates. Less glucose is absorbed because the carbohydrates are not broken down into glucose molecules. In diabetic patients, the short-term effect of these drugs therapies is to decrease current blood glucose levels: the long term effect is a small reduction in hemoglobin-A1c level.

Adult Dose: Usually, Voglibose tablets are orally administered in a single dose of 0.2 mg, 3 times a day, before each meal. If the effect is not sufficient, the quantity of a single dose may be increased up to 0.3 mg.

Paediatrics: The safety and effectiveness of Voglibose in children has not been established.

Geriatrics: Since elderly patients generally have a physiological hypofunction, it is desirable that such caution should be taken as starting the administration at a lower dose (e.g. 0.1 mg at a time). Furthermore, this drug should be carefully administered under close observation, through the course of the disease condition, with careful attention to the blood sugar level and the onset of gastrointestinal symptoms.

Dosage in Renal Failure: Voglibose is poorly absorbed after oral doses and renal excretion is negligible, suggesting that no dose adjustment is required. However, pharmacokinetic studies in patients with renal insufficiency are not available.

Volibo should be administered with care when co-administered with the following drugs: Antidiabetic drugs- Derivative(s) of sulfonylamide and sulfonylurea, biguanide derivatives, insulin preparations and improving agents for insulin resistance.

For the concomitant use of anti-diabetic drugs and the drugs which enhance or diminish the hypoglycaemic action of antidiabetic drugs:

• Drugs enhancing the hypoglycaemic action of antidiabetic drugs: β-blockers, salicylic acid preparations, monoamine oxidase inhibitors, fibrate derivatives, warfarin, etc.
• Drugs diminishing the hypoglycaemic action of antidiabetic drugs: Adrenaline, adrenocortical hormone, thyroid hormone etc.

Contraindicated in patients with Hypersensitivity to Voglibose or to any of the excipients; Diabetic ketoacidosis, diabetic pre-coma, severe infection, before and after operation or with serious trauma; gastrointestinal obstruction or predisposed to it.

Volibo unlikely to produce hypoglycaemia in overdose, but abdominal discomfort and diarrhea may occur. Moreover loose stools, abdominal pain, constipation, loss of appetite, urge to vomit (nausea), vomiting, heartburn, increased gas, and intestinal obstruction like symptoms due to increased intestinal gas may cause. Oral hypoglycaemic agents plus Volibo may cause hypoglycaemia (0.1% to <5%), delay in digestion and absorption of disaccharides, fulminant hepatitis, serious liver dysfunction with increased liver enzymes, jaundice, anemia, numbness, edema, blurred vision, hot flushes, malaise, weakness, hyperkalemia, increased pancreatic enzyme (serum amylase).

The safety of Voglibose in pregnancy has not been established. However, no adequate and well controlled studies have been found on pregnant women. Although the levels of Voglibose reached in human milk are exceedingly low, it is recommended that Voglibose may not be administered to such women.

The administration of Volibo tablets should be limited to patients who have established diabetes as there are certain other disease conditions such as abnormal glucose tolerance and positive urinary sugar that represent diabetes-like symptoms (renal glycosuria, senile abnormal glucose tolerance, abnormal thyroid function, etc.) In patients who are being managed with lifestyle modifications (diet and/or exercise), Volibo must be given only when the 2-hour postprandial blood glucose levels are ≥200 mg/dL. During administration of Volibo, disease progression should be closely observed with monitoring of blood glucose levels at regular intervals. If the effect on postprandial glucose levels is not satisfactory even after the administration of Volibo for 2 to 3 months (postprandial glucose ≥200mg/dL), consider a change to more appropriate treatment. After administration of Volibo, if sufficient control of blood glucose is achieved (postprandial glucose ≤160 mg/dL) and can satisfactorily be maintained with lifestyle therapy or with additional use of oral hypoglycaemic drugs or insulin preparations, the administration of Volibo tablet should be discontinued, and subsequent progresses of disease should be monitored.

Unlike sulfonylureas or insulin, an overdose of Volibo tablets will not result in hypoglycaemia. An overdose may result is transient increase in flatulence, diarrhoea and abdominal discomfort. Because of lack of extra-intestinal effects soon with Volibo, no serious systemic reactions are expected in the event of an overdose.

Alpha-Glucosidase inhibitor

Store in a cool (below 30°C) and dry place, away from light. Keep out of the reach of children.